BioSpace News Archive

The Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim today announced the first patient has enrolled in a new clinical study to investigate the effect of nintedanib in adult patients having acute lung injury following COVID-19 infection.

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced positive results from ReoGlio, an investigator-sponsored, phase 1b trial evaluating the combination of pelareorep and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant temozolomide for the treatment of glioblastoma multiforme (GBM).

Invitation-Only Digital Gathering Encouraged Collaboration and Delivered Value to Customers

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced it has been ranked 13th in revenue growth among all medical device companies in

Covis Group S.à r.l. (“Covis”) today announced that data demonstrating that the investigational anticoagulant reversal agent ciraparantag binds to unfractionated heparin, low molecular weight heparin (LMWH) and direct oral anticoagulants (DOACs) were published in Blood, the journal of the American Society of Hematology (ASH).

LimaCorporate is proud to announce that the U.S. Food and Drug Administration (FDA) has approved the Investigational Device Exemption (IDE) to start the clinical trial of the SMR Stemless Reverse Shoulder System. The FDA approval allows LimaCorporate to start a randomized, multi-center comparative clinical trial on the SMR Ste

With the common symptoms of flu, COVID-19 and Lyme disease all converging to form a frightening respiratory season, health care professionals nationwide will converge themselves to join an important webinar on Dec. 3 focused on how to correctly diagnose and treat these look-alike conditions. The webinar is being sponsored by Quidel, the California-based diagnostic health care manufacturer known for successfully developing ra

Healthy male participants who take a novel antioxidant that specifically targets the powerhouse of the cells, mitochondria, sees attenuation in exercise induced mitochondria DNA (mtDNA) damage in lymphocytes and muscle.

Talix, a SaaS solution for both payers and healthcare providers to manage their patient information, announced a patent awarded by the U.S. Patent and Trademark Office entitled, “Health Information System for Searching, Analyzing and Annotating Patient Data,” patent number 10,755,804

Invitae (NYSE: NVTA), a leading medical genetics company, today presented study findings that show nine percent of patients with pancreatic cancer had genetic changes in DNA damage repair (DDR) genes that would make them eligible for PARP inhibitor therapy or clinical treatment trials.